All Pharma News
price-trendAsk Us
Moderna and Myrtelle among those picked for FDA rare disease programme

Moderna and Myrtelle among those picked for FDA rare disease programme
Jenna Philpott PHARMACEUTICAL TECHNOLOGY
06 Jun 2024
Share Share
Myrtelle: FDA Selects rAAV-Olig001-ASPA For Canavan START Program

Myrtelle: FDA Selects rAAV-Olig001-ASPA For Canavan START Program
PR NEWSWIRE
05 Jun 2024
Share Share
Myrtelle Announces Presentation of Data in Study of rAAV-Olig001-ASPA

Myrtelle Announces Presentation of Data in Study of rAAV-Olig001-ASPA
BUSINESSWIRE
10 Oct 2023
Share Share
Myrtelle to Present Positive Post-Treatment Data in Study of rAAV-Olig001-ASPA

Myrtelle to Present Positive Post-Treatment Data in Study of rAAV-Olig001-ASPA
BUSINESSWIRE
31 May 2023
Share Share
Myrtelle Announces Positive Data in Phase 1/2 Trial of rAAV-Olig001-ASPA

Myrtelle Announces Positive Data in Phase 1/2 Trial of rAAV-Olig001-ASPA
BUSINESSWIRE
09 Jan 2023
Share Share
Myrtelle and Forge Biologics Form Manufacturing Partnership

Myrtelle and Forge Biologics Form Manufacturing Partnership
CONTRACTPHARMA
07 Oct 2022
Share Share
CNS-focused gene therapy biotech forges manufacturing deal for hearing loss drug

CNS-focused gene therapy biotech forges manufacturing deal for hearing loss drug
Paul Schloesser ENDPTS
06 Oct 2022
Share Share
Myrtelle Completes Dosing of 8 Patients with Canavan Disease in Its Phase 1/2

Myrtelle Completes Dosing of 8 Patients with Canavan Disease in Its Phase 1/2
BUSINESSWIRE
04 Oct 2022
Share Share
Myrtelle and Forge Biologics Announce Viral Vector and Plasmid DNA Cgmpmfg

Myrtelle and Forge Biologics Announce Viral Vector and Plasmid DNA Cgmpmfg
BUSINESSWIRE
03 Oct 2022
Share Share
Myrtelle concludes preliminary stage of Canavan disease gene therapy trial

Myrtelle concludes preliminary stage of Canavan disease gene therapy trial
CLINICALTRIALSARENA
12 Jan 2022
Share Share